Popular search terms:
Search Results
27 results found-
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia
https://www.cslbehring.com.au/news/2018/life-saving-medicines-donated-for-patients-in-the-developing-world -
News
CSL Behring Australia is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
https://www.cslbehring.com.au/news -
Our Company | CSL Behring Australia
CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.
https://www.cslbehring.com.au/our-company -
Research and Development Capabilities
At CSL Behring, innovation is in our DNA. Learn about our commitment to the research & development of new biotherapies for rare and serious diseases.
https://www.cslbehring.com.au/research-and-development/research-and-development-capabilities -
Newsroom
CSL Behring Australia is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
https://www.cslbehring.com.au/news/newsroom -
Australian PI . Biostate (FVIII / VWF)
the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/biostate-au-pi-v2600.pdf -
Biostate Data Sheet
the prophylaxis and treatment of non-surgical and surgical bleeding associated with FVIII deficiency due to haemophilia A.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds1800.pdf -
PowerPoint Presentation
IV and SC for CIDP Haemophilia +16% •
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2019.pdf -
NEW ZEALAND DATA SHEET 1 PRODUCT NAME MonoFIX®-VF 500 IU powder and diluent (10 mL) for solution for injection
MonoFIX®-VF NZ DS 5.00 Page 1 of 13 NEW ZEALAND DATA SHEET 4 CLINICAL PARTICULARS 4.1 Therapeutic indications MonoFIX®-VF is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia B. MonoFIX®-VF is not indicated for the treatment of factor II, VII or X deficiencies because it does not contain therapeutic levels of these coagulation factors.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/monofixvf-nz-ds-500.pdf -
NEW ZEALAND DATA SHEET 1 PRODUCT NAME Prothrombinex®-VF powder and diluent for solution for injection 2 QUALITATIVE AND QUANTITA...
Isolated deficiency of factor II or factor X is very rare but in severe form they cause a bleeding tendency similar to that seen in classical haemophilia.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/prothrombinexvf-nz-ds-2000.pdf